Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings
Open Access
- 26 April 2006
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 295 (16) , 1921-1928
- https://doi.org/10.1001/jama.295.16.1921
Abstract
The Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA) approves 25 to 30 new chemical entities each year, often relying in its decision making on the advice of advisory committees composed of outside scientific experts. In 2001, 21% of these approvals were preceded by an advisory committee meeting.1Keywords
This publication has 0 references indexed in Scilit: